Italia markets close in 7 hours 10 minutes

Ligand Pharmaceuticals Incorporated (LGND)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
88,48+1,27 (+1,46%)
Alla chiusura: 04:00PM EDT
88,48 0,00 (0,00%)
Dopo ore: 04:09PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente87,21
Aperto86,66
Denaro0,00 x 1300
Lettera0,00 x 1000
Min-Max giorno85,53 - 88,51
Intervallo di 52 settimane72,57 - 169,98
Volume51.316
Media Volume158.288
Capitalizzazione1,492B
Beta (5 anni mensile)1,22
Rapporto PE (ttm)67,54
EPS (ttm)1,31
Prossima data utili27 lug 2022 - 01 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendo02 lug 2010
Stima target 1A182,50
  • GlobeNewswire

    Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs

    Key Opinion Leader (KOL) webinar scheduled for Wednesday, June 15, at 10:00 a.m. EDTCOLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it will host a virtual update on its ELAINE Phase 2 clinical programs on Wednesday, June 15 at 10:00 a.m. EDT. The event will feature presentations from Key

  • GlobeNewswire

    Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    COLUMBUS, Ohio, April 28, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 3-7 at McCormick Place in Chicago and online. Details of the presentations are as follows: Title: Open-lab

  • GlobeNewswire

    Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium

    Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK inhibitor may limit tumor progression in aromatase inhibitor (AI) resistant tumors not resistant due to an ESR1 mutationCOLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that the company, in collaboratio